Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET

Company Participants

Laurence Watts - Investor Relations, Gilmartin Group

Benjamin Zeskind - President and Chief Executive Officer

Brett Hall - Chief Scientific Officer

Scott Barrett - Chief Medical Officer

Mallory Morales - Vice President of Finance, Treasurer

Conference Call Participants

Swapnil Malekar - Piper Sandler

Jeffrey Hung - Morgan Stanley

Mark Breidenbach - Oppenheimer & Co. Inc.

Michael Schmidt - Guggenheim Partners

Operator

Welcome to the Immuneering Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, Monday, March 6, 2023.

I would now like to turn the conference over to Laurence Watts of Gilmartin Group. Please go ahead.

Laurence Watts

Thank you, operator. Joining us on the call today from Immuneering are Chief Executive Officer, Ben Zeskind; Chief Scientific Officer, Brett Hall; Chief Medical Officer, Scott Barrett; and Vice President of Finance and Treasurer; Mallory Morales.

During this conference call management will make forward-looking statements, including statements relating to guidance and timing of data readouts for IMM-1-104 and IND submission of IMM-6-415. These forward-looking statements are based on the company’s current expectations and inherently involved significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.

Factors that could cause results to be different from these statements include factors the company described in the section titled risk factors on an annual report on Form 1-K filed with the SEC today, March 6, 2023. Immuneering undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes and its expectations.

With that, I will now turn the call over to Chief Executive Officer, Ben Zeskind. Ben?

Benjamin Zeskind

Thank you, Laurence. Good afternoon, everyone, and thank you for joining our fourth quarter and full year 2022 financial results conference call. The first such call we are hosting in our company’s 15-year history. Let me start by assuring you that we do not plan to host an earnings call every single quarter, we will probably do them more than once every 15 years, though, maybe somewhere in between. Today, we have a lot to say, though, about our plan for the upcoming year, and about the timing of our ongoing clinical trials.